AAAAAA
Results:
1-9
|
Results: 9
Authors:
Sandrock, TM
Risley, B
Richards, BT
Poritz, MA
Austin, HA
Yoo, S
Kim, MKH
Roth, B
Repetny, K
Hsu, F
Stump, M
Teng, DHF
Kamb, A
Citation: Tm. Sandrock et al., Exogenous peptide and protein expression levels using retroviral vectors in human cells, MOL THER, 4(5), 2001, pp. 398-406
Authors:
Schiffmann, R
Kopp, JB
Austin, HA
Sabnis, S
Moore, DF
Weibel, T
Balow, JE
Brady, RO
Citation: R. Schiffmann et al., Enzyme replacement therapy in Fabry disease - A randomized controlled trial, J AM MED A, 285(21), 2001, pp. 2743-2749
Authors:
Illei, GG
Austin, HA
Crane, M
Collins, L
Gourley, MF
Yarboro, CH
Vaughan, EM
Kuroiwa, T
Danning, CL
Steinberg, AD
Klippel, JH
Balow, JE
Boumpas, DT
Citation: Gg. Illei et al., Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis, ANN INT MED, 135(4), 2001, pp. 248-257
Authors:
Balow, JE
Austin, HA
Citation: Je. Balow et Ha. Austin, Progress in the treatment of proliferative lupus nephritis, CURR OP NEP, 9(2), 2000, pp. 107-115
Authors:
Austin, HA
Balow, JE
Citation: Ha. Austin et Je. Balow, Treatment of lupus nephritis, SEM NEPHROL, 20(3), 2000, pp. 265-276
Authors:
Balow, JE
Boumpas, DT
Austin, HA
Citation: Je. Balow et al., New prospects for treatment of lupus nephritis, SEM NEPHROL, 20(1), 2000, pp. 32-39
Authors:
Boumpas, DT
Tassiulas, IO
Fleisher, TA
Vaughan, E
Piscitelli, S
Kim, Y
Pucino, F
Balow, JE
Austin, HA
Citation: Dt. Boumpas et al., A pilot study of low-dose fludarabine in membranous nephropathy refractoryto therapy, CLIN NEPHR, 52(2), 1999, pp. 67-75
Authors:
Austin, HA
Balow, JE
Citation: Ha. Austin et Je. Balow, Natural history and treatment of lupus nephritis, SEM NEPHROL, 19(1), 1999, pp. 2-11
Authors:
Austin, HA
Citation: Ha. Austin, Clinical evaluation and monitoring of lupus kidney disease, LUPUS, 7(9), 1998, pp. 618-621
Risultati:
1-9
|